Pharmacological inhibition of beta-catenin in hepatoblastoma cells

Pediatric Surgery International

Volumn 29, Issue 2, 2013, Pages 141-149

  Ellerkamp, V ^a   Lieber, J ^a   Nagel, C ^a   Wenz, J ^a   Warmann, S W ^a   Fuchs, J ^a   Armeanu Ebinger, S ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Beta catenin; Celecoxib; Hepatoblastoma; ICG 001; Kinase; MET; Orthotopic; SU11274

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; BROXURIDINE; CELECOXIB; CISPLATIN; ETODOLAC; ICG 001; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BETA CATENIN; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; ETODOLAC; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINONES; SULFONAMIDES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 84878352234     PISSN: 01790358     EISSN: 14379813     Source Type: Journal    
DOI: 10.1007/s00383-012-3237-9     Document Type: Article

References (51)

1. Zsiros J, Maibach R, Shafford E, Brugieres L, Brock P, Czauderna P, Roebuck D, Childs M, Zimmermann A, Laithier V, Otte JB, de Camargo B, MacKinlay G, Scopinaro M, Aronson D, Plaschkes J, Perilongo G (2010) Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol Off J Am Soc Clin Oncol 28(15):2584-2590. doi: 10.1200/JCO.2009.22.4857
2. Zimmermann A (2005) The emerging family of hepatoblastoma tumours: from ontogenesis to oncogenesis. Eur J Cancer 41(11):1503-1514. doi: 10.1016/j.ejca.2005.02.035
3. Honda S, Arai Y, Haruta M, Sasaki F, Ohira M, Yamaoka H, Horie H, Nakagawara A, Hiyama E, Todo S, Kaneko Y (2008) Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma. Br J Cancer 99(11):1891-1899. doi: 10.1038/sj.bjc.6604754
4. Rainier S, Dobry CJ, Feinberg AP (1995) Loss of imprinting in hepatoblastoma. Cancer Res 55(9):1836-1838
5. Lopez-Terrada D, Gunaratne PH, Adesina AM, Pulliam J, Hoang DM, Nguyen Y, Mistretta TA, Margolin J, Finegold MJ (2009) Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and notch pathway activation in DLK + precursors. Hum Pathol 40(6):783-794. doi: 10.1016/j.humpath.2008.07.022
6. Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T (1999) Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 59(2):269-273
7. Koch A, Waha A, Hartmann W, Hrychyk A, Schuller U, Waha A, Wharton KA Jr, Fuchs SY, von Schweinitz D, Pietsch T (2005) Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin cancer Res Off J Am Assoc Cancer Res 11(12):4295-4304. doi: 10.1158/1078-0432.CCR-04-1162
8. Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G, Buendia MA (2000) Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 19(4):498-504. doi: 10.1038/sj.onc.1203356
9. Yamaoka H, Ohtsu K, Sueda T, Yokoyama T, Hiyama E (2006) Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors. Oncol Rep 15(3):551-556
10. Purcell R, Childs M, Maibach R, Miles C, Turner C, Zimmermann A, Sullivan M (2011) HGF/c-Met related activation of beta-catenin in hepatoblastoma. J Exp Clini Cancer Res CR 30:96. doi: 10.1186/1756-9966-30-96
11. Park WS, Oh RR, Park JY, Kim PJ, Shin MS, Lee JH, Kim HS, Lee SH, Kim SY, Park YG, An WG, Jang JJ, Yoo NJ, Lee JY (2001) Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. J Pathol 193(4):483-490
12. Gavert N, Ben-Ze'ev A (2007) Beta-catenin signaling in biological control and cancer. J Cell Biochem 102(4):820-828. doi: 10.1002/jcb.21505
13. Klaus A, Birchmeier W (2008) Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8(5):387-398. doi: 10.1038/nrc2389
14. Ellerkamp V, Armeanu-Ebinger S, Wenz J, Warmann SW, Schafer J, Ruck P, Fuchs J (2011) Successful establishment of an orthotopic hepatoblastoma in vivo model in NOD/LtSz-scid IL2Rgammanull mice. PLoS ONE 6(8):e23419. doi: 10.1371/journal.pone.0023419
15. MacDonald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17(1):9-26. doi: 10.1016/j.devcel.2009.06.016
16. Monga SP, Mars WM, Pediaditakis P, Bell A, Mule K, Bowen WC, Wang X, Zarnegar R, Michalopoulos GK (2002) Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 62(7):2064-2071
17. Pietsch T, Fonatsch C, Albrecht S, Maschek H, Wolf HK, von Schweinitz D (1996) Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Investig J Tech Methods Pathol 74(4):809-818
18. Doi I (1976) Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann = Gan 67(1):1-10
19. Lieber J, Kirchner B, Eicher C, Warmann SW, Seitz G, Fuchs J, Armeanu-Ebinger S (2010) Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells. Pediatr Blood Cancer 55(6):1089-1095. doi: 10.1002/pbc.22740
20. Dewerth A, Wonner T, Lieber J, Ellerkamp V, Warmann SW, Fuchs J, Armeanu-Ebinger S (2012) In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma. Pediatr Surg Int 28(6):579-589. doi: 10.1007/s00383-012-3086-6
21. Oue T, Yoneda A, Uehara S, Yamanaka H, Fukuzawa M (2009) Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies. J Pediatr Surg 44(2):377-380. doi: 10.1016/j.jpedsurg.2008.10.088
22. Warmann S, Hunger M, Teichmann B, Flemming P, Gratz KF, Fuchs J (2002) The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model. Cancer 95(8):1795-1801. doi: 10.1002/cncr.10858
23. Sawyers C (2004) Targeted cancer therapy. Nature 432(7015):294-297. doi: 10.1038/nature03095
24. He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M, McCormick F, Jablons DM (2004) A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 6(1):7-14
25. Lee JS, Hur MW, Lee SK, Choi WI, Kwon YG, Yun CO (2012) A novel sLRP6E1E2 inhibits canonical Wnt signaling, epithelial-to-mesenchymal transition, and induces mitochondria-dependent apoptosis in lung cancer. PLoS ONE 7(5):e36520. doi: 10.1371/journal.pone.0036520
26. Purcell R, Childs M, Maibach R, Miles C, Turner C, Zimmermann A, Czauderna P, Sullivan M (2011) Potential biomarkers for hepatoblastoma: results from the SIOPEL-3 study. Eur J Cancer. doi: 10.1016/j.ejca.2011.10.019
27. Ueda Y, Hiyama E, Kamimatsuse A, Kamei N, Ogura K, Sueda T (2011) Wnt signaling and telomerase activation of hepatoblastoma: correlation with chemosensitivity and surgical resectability. J Pediatr Surg 46(12):2221-2227. doi: 10.1016/j.jpedsurg.2011.09.003
28. Curtin JC, Lorenzi MV (2010) Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 1(7):563-577
29. Herencia C, Martinez-Moreno JM, Herrera C, Corrales F, Santiago-Mora R, Espejo I, Barco M, Almaden Y, de la Mata M, Rodriguez-Ariza A, Munoz-Castaneda JR (2012) Nuclear translocation of beta-catenin during mesenchymal stem cells differentiation into hepatocytes is associated with a tumoral phenotype. PLoS ONE 7(4):e34656. doi: 10.1371/journal.pone.0034656
30. Zulehner G, Mikula M, Schneller D, van Zijl F, Huber H, Sieghart W, Grasl-Kraupp B, Waldhor T, Peck-Radosavljevic M, Beug H, Mikulits W (2010) Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. Am J Pathol 176(1):472-481. doi: 10.2353/ajpath.2010.090300
31. Curia MC, Zuckermann M, De Lellis L, Catalano T, Lattanzio R, Aceto G, Veschi S, Cama A, Otte JB, Piantelli M, Mariani-Costantini R, Cetta F, Battista P (2008) Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations. Mod Pathol Off J US Can Acad Pathol Inc 21(1):7-14. doi: 10.1038/modpathol.3800977
32. Ranganathan S, Tan X, Monga SP (2005) Beta-catenin and met deregulation in childhood Hepatoblastomas. Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Patholo Soc 8(4):435-447. doi: 10.1007/s10024-005-0028-5
33. Gupta K, Rane S, Das A, Marwaha RK, Menon P, Rao K (2012) Relationship of beta-catenin and postchemotherapy histopathologic changes with overall survival in patients with hepatoblastoma. J Pediatr Hematol Oncol. doi: 10.1097/MPH.0b013e3182580471
34. Park SE, Yoo HS, Jin CY, Hong SH, Lee YW, Kim BW, Lee SH, Kim WJ, Cho CK, Choi YH (2009) Induction of apoptosis and inhibition of telomerase activity in human lung carcinoma cells by the water extract of Cordyceps militaris. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc 47(7):1667-1675. doi: 10.1016/j.fct.2009.04.014
35. Shalaby T, Hiyama E, Grotzer MA (2010) Telomere maintenance as therapeutic target in embryonal tumours. Anti-Cancer Agents Med Chem 10(3):196-212
36. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94(4):252-266
37. Greenspan EJ, Madigan JP, Boardman LA, Rosenberg DW (2011) Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. Cancer Prev Res (Phila) 4(1):161-171. doi: 10.1158/1940-6207.CAPR-10-0021
38. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107(4):1183-1188
39. Grosch S, Maier TJ, Schiffmann S, Geisslinger G (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98(11):736-747. doi: 10.1093/jnci/djj206
40. Behari J, Zeng G, Otruba W, Thompson MD, Muller P, Micsenyi A, Sekhon SS, Leoni L, Monga SP (2007) R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells. J Hepatol 46(5):849-857. doi: 10.1016/j.jhep.2006.11.017
41. Yao H, Ashihara E, Maekawa T (2011) Targeting the Wnt/beta-catenin signaling pathway in human cancers. Expert Opin Ther Targ 15(7):873-887. doi: 10.1517/14728222.2011.577418
42. Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP, Richel DJ (2008) Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res 68(4):1213-1220. doi: 10.1158/0008-5472.CAN-07-5172
43. Andre N, Abed S, Orbach D, Alla CA, Padovani L, Pasquier E, Gentet JC, Verschuur A (2011) Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget 2(12):960-965
44. Buendia MA (2002) Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med Pediatr Oncol 39(5):530-535. doi: 10.1002/mpo.10180
45. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo JL, Kim HY, Moon SH, Ha JR, Kahn M (2004) A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci USA 101(34):12682-12687. doi: 10.1073/pnas.0404875101
46. Henderson WR Jr, Chi EY, Ye X, Nguyen C, Tien YT, Zhou B, Borok Z, Knight DA, Kahn M (2010) Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci USA 107(32):14309-14314. doi: 10.1073/pnas.1001520107
47. Goodman RH, Smolik S (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev 14(13):1553-1577
48. Gao J, Inagaki Y, Song P, Qu X, Kokudo N, Tang W (2012) Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. Pharmacol Res Off J Italian Pharmacol Soc 65(1):23-30. doi: 10.1016/j.phrs.2011.11.011
49. Lieber J, Ellerkamp V, Wenz J, Kirchner B, Warmann SW, Fuchs J, Armeanu-Ebinger S (2012) Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells. Pediatr Surg Int 28(2):149-159. doi: 10.1007/s00383-011- 2988-z
50. Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC (2010) Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res 3:11. doi: 10.1186/1757-2215-3-11
51. Wang J, Zhou D, He X, Wang Y, Hu W, Jiang L, Dou J (2011) Effect of downregulated beta-catenin on cell proliferative activity, the sensitivity to chemotherapy drug and tumorigenicity of ovarian cancer cells. Cell Mol Biol 57(Suppl):OL1606-OL1613